Signadori Bio
PrivateLast Round
Seed
May 6, 2026
Total Funding Raised
$13M
Company Overview
Signadori Bio is a biopharmaceutical company developing a next-generation, off-the-shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Signadori Bio Comps
Public and private peers based on sector, stage, and business model.
Signadori Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 6, 2026 |
Signadori Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Taiho Ventures | Seed |
| Sofinnova Partners | Seed |
| Invivo Partners | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 6, 2026
$13M round with Taiho Ventures and Invivo Partners.
- Oct 16, 2025
Grew 150% QoQ, from 2 to 5 employees.
Signadori Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Signadori Bio's valuation, stock price, and market status.
